Exclusion Criteria for all subjects:~* Participation in a therapeutic clinical trial at any time during the
study;~* Abnormal corrected QT interval using Bazett's formula (QTcB; defined as > 450 ms for men and > 470 ms
for women) as determined on ECG;~* Any significant neurologic disease other than suspected incipient
Alzheimer's disease, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure
hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple
sclerosis, or history of significant head trauma followed by persistent neurologic deficits or known structural
brain abnormalities, including lacunes in critical memory structures including the hippocampus and
parahippocampal cortex;~* Major depression, bipolar disorder within the past 1 year;~* History of alcohol or
drug dependence;~* Any significant systemic illness or unstable medical condition, which could lead to
difficulty complying with the protocol;~* General surgery within the last 3 months;~* Sensory impairment (poor
vision or hearing) significant enough to interfere with ability to provide valid cognitive test data;~*
Treatment within the last six months with antidepressants, neuroleptics, sedative hypnotics, or
glucocorticoids;~* Treatment within the last six months with medications metabolized by the CYP2C9 or CYP2C19
enzymes, most notably clopidogrel and proton pump inhibitors;~* Concurrent use of a CYP3A inhibitor, including
grapefruit juice, and St. John's Wort;~* Exceptions to these guidelines may be considered on a case-by-case
basis at the discretion of the PI.
